Why is Aurobindo Pharma falling/rising?

As of 02-Sep, Aurobindo Pharma Ltd. is experiencing a decline in its stock price, currently at 1,021.40, which reflects a decrease of 3.6 points or 0.35%. The stock has been underperforming, having fallen consecutively for the last five days, resulting in a total decline of 4.2% during this period. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, just 2.65% away from Rs 994.35. Over the past year, Aurobindo Pharma has generated a return of -34.02%, significantly underperforming the broader market, which has seen a decline of only 2.91%. The company's profits have also decreased by 6.1%, contributing to the negative sentiment surrounding its stock.
Broader market context shows that Aurobindo Pharma's recent performance is notably weaker than the benchmark, with a 1-week return of -2.62% compared to the Sensex's -0.78%. This underperformance is compounded by a low debt-to-equity ratio and a return on equity of 10.7, which, while indicating an attractive valuation, does not offset the poor long-term growth prospects, as evidenced by a mere 4.40% annual growth in operating profit over the last five years. Furthermore, the company's flat results in June, including a significant drop in PAT, have raised concerns among investors, leading to decreased participation and a decline in delivery volume. High institutional holdings at 41.31% suggest that more sophisticated investors are aware of these challenges, further influencing the stock's downward trajectory.